No, I'm saying I talked to one of his associates personally. And I never claimed to know 50. You made that claim. You are the one that exaggerated. However, I have e-mailed 50 posters, 40 here and 10 elsewhere, who appeared to be long the stock. Of those, about a dozen responded and those are the ones I'm keeping updated.
I know Ray. I'm just wanting Drew to make a substantive post. He does nothing but taunt. At least Ray had something significant to say, though I found him to be far too optimistic. Anybody can throw rocks and resort to name-calling and taunting. There are few who back up their positions, long or short, with a well-reasoned case. Those are the ones I really respect.
to be clear, a dozen active members. There are more than 40 we have tried to contact but only a dozen have responded in any significant way on a regular basis.
We've been through this before, Drew. I never claimed 50. You did. I'm in touch with about a dozen members of this board and others, including brjj and one of his associates.
Yes, Drew, I'm interested in reading one of these so-called Ray novels you claim to have. E-mail Alectric at my yahoo address. Seriously. I don't think you have one.
If you are referring to the 19.9% stake in Pyrexar, you need to read the SEC filing of April 1, 2015. As to Microsulis, I was referring to a company with an inferior product that was bought out for $21M, all told. My point is, the company is worth more than the $1M that you think it is worth.
If you add in the $1M in liabilities, Microsulis actually sold for $21M, plus Perseon has about $65M in net operating losses which are worth as much as $26M in tax offsets to profits (at a corporate federal tax rate of 35% and state of 5%).
Disagree. PRSN has a 19.9% stake in Pyrexar worth probably $2M minimum. They will probably get multiple offers for their MTX technology. A simple, single probe system went for $20M two years ago:
Mar 26 2012
AngioDynamics, Inc., a medical device company, entered into co-marketing agreement with Microsulis Medical Limited...by investing $5m in preferred equity.
January 23, 2013
ALBANY, N.Y., Jan. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics)...announced it has exercised the option to purchase certain assets of Microsulis Medical Ltd..., based in Denmead, England, is a medical device company specializing in minimally invasive, microwave ablation technology...has systems in more than 80 hospitals world-wide..The device was CE Marked in February 2010 and 510(k) cleared by the U.S. Food and Drug Administration (FDA) in August 2010....In March 2012, AngioDynamics and Microsulis established a strategic relationship granting AngioDynamics exclusive distribution rights to market and sell the Accu2i pMTA microwave ablation system in all markets outside the United States from May 2012 through December 2013. The agreement included the exclusive option to purchase substantially all of the global assets and certain liabilities of Microsulis, including its microwave ablation technology and worldwide distribution rights...Under the terms of the definitive agreement, AngioDynamics will acquire certain assets of Microsulis Medical for an upfront cash payment of $10.0 million, and $5.0 million on December 31, 2013, utilizing cash on hand. AngioDynamics will also assume up to $1 million of liabilities. Microsulis stakeholders could also receive additional cash consideration, based on Microsulis' performance over the next 9 years.
No fibbing, you can ask some of the members on this board. They are getting them. You are not. Jealous, yet?
The problem with the OTC is it gets much more difficult to raise capital and the spreads are wider. Plus these stocks are not marginable. I would not buy any more warrants if the stock hits .15. Might as well buy the stock, get immediate benefit, plus if the company goes Chapter 7, you will get something in liquidation, assuming a buyer steps up to take the technology. With warrants, you get nothing.
l've seen some of the Greek shippers fall faster, but it has to be in the top 5. I warned the CEO about the death spiral the company faced more than a year ago (actually in early 2013 not too long after he first joined the company), and he blew me off. I believe what has been happening is what few institutions the company had behind them (Empery, etc) have been closing out their positions by the end of the quarter. Institutional support is down 12% in the last 3 months. I believe by YE, shareholder equity will be below $2.5M, and the company will be faced with delisting in late January, early February when the annual report is filed, not to mention a going concern opinion from the auditors. At that point, they will be out of options, as no investment banker will do a firm commitment any more. That's when the company will accept a buyout offer, merger, or file Chapter 7 liquidation.
It's available to everyone except you.
I think he means the lower the price, the greater the reward, assuming the risk remains constant. You'd think the insiders would be all over this at these prices. Something does seem amiss. This quarter's results will be telling. Regardless, I believe the day of reckoning will be end of January, early February.
No real reason for the name change other than spinning off the hyperthermia business and wanting a fresh start under a new CEO. Name change also makes it more difficult to search on the company's past without knowing its former name but it's all still in the SEC filings.
At least a couple of microwave ablation companies have sold that were not profitable. Google Microsulis. Sold for $20M. Had a single probe device. Vivant sold for over $100M in today's dollars. A few million for this company could save a larger entity the hassle of waiting on FDA approval, give them instant access to Europe as well.
$1 minimum not the one to worry about, it's the $2.5M in shareholder equity. BK would be Chapter 7 since no debt, liquidation proceeds go to shareholders, but more likely there will be a merger with a larger entity. Perhaps, Pyrexar will buy them for a song ;-)
BERLIN (Reuters) - Audi said 2.1 million cars worldwide were fitted with the software that allowed parent Volkswagen to cheat U.S. emission tests.
Note the Company has changed its fiscal year end from August to December and has undergone a 1:10 reverse split since the SEC filing of November 10, 2014. The inducement award is now 140,000 shares at an exercise price of $4.60. The net proceeds raised in the July 2015 offering was $4.3M, short of the $5M required for salary re-negotiation, however, it's unclear if the exercise of the overallotment by the underwriter and the buy-in of executives is included in the $4.3M or on top of the $4.3M. If it is on top of the $4.3M, then the $5M condition may have been met.